Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.

8 In addition, the Towards a Revolution in COPD Health (TORCH) study showed a 17% relative reduction in mortality over 3 years for patients receiving salmeterol (SAL)/fluticasone propionate (FP), although this just failed to reach significance. 9 Furthermore, systematic reviews of the literature suggest that a combination of ICSs and LABAs reduces mortality by approximately 20%, whereas neither tiotropium nor LABA by itself modifies all-cause mortality in COPD. 10 ICSs have been found to be associated with a reduction in mortality rate w

also in 279 other papers